Effect of Myoinositol and Metformin in combination on clinical and hormonal profile in patients of polycystic ovarian syndrome

Tripti Nagaria, Arpita Mohapatra, Jyoti Jaiswal


Background: Polycystic ovarian syndrome (PCOS) also known as hyperandrogenic anovulation syndrome or Stein – Leventhal syndrome is an endocrine disorder, characterized by anovulation, oligomenorrhea, amenorrhea, features of androgenic hormone excess (hirsutism, acne, alopecia, seborrhea) and insulin resistance. The global prevalence ranges from 2.2% to 26%. 

Methods: A prospective observational study was conducted from December 2015 to December 2016 in Department of Obstetrics and Gynecology at Pt. Jawahar Lal Nehru Memorial medical college and associated Dr. Bhim Rao Ambedkar memorial hospital, Raipur (C.G.) after obtaining permission of ethical committee of the institute to evaluate the effect of myoinositol and metformin on clinical profile in patients of polycystic ovarian syndrome. 70 women were included in the study who received a combination of myoinositol 600mg and metformin 500mg (twice a day) for 3 months for the management of PCOS. Prior to the start of the therapy, a detailed history and baseline investigations were recorded. Cases were reassessed at the end of three months of therapy for evaluation of change in clinical and hormonal profile.

Results: 90.09% (63/70) cases showed improvement in the menstrual complaints. Spontaneous onset of menses occurred in all the cases presented with amenorrhea, in nearly 90% within 2 months of start of treatment. Regularization of cycles was observed in nearly 50% of patients with infrequent menses. Amongst all the cases with cutaneous manifestations, maximum improvement was seen in cases of acne (4/6) i.e. 66.66%. 25% (5/20) patients with infertility conceived during the study period.

Conclusions: Myoinositol with metformin in combination has resulted in significant improvement in the clinical profile with reduction in individual drug dosage in cases with PCOS.


Metformin, Myoinositol, PCOS

Full Text:



Joshi B, Mukherjee S, Patil A, Purandare A, Chauhan S, Vaidya R. A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. Indian J Endocrinol Metabol. 2014;18(3):317.

Chang RJ, Nakamura RM, Judd Hl, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clinical Endocrinol Metabol. 1983;57(2):356-9.

Buyalos RP, Geffner ME, Bersch N, Judd HL, Watanabe RM, Bergman RN, et al. Insulin and insulin-like growth factor-I responsiveness in polycystic ovarian syndrome. Fertil steril. 1992;57(4):796-803.

Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clinical Endocrinol Metabol. 1991;72(1):83-9.

Nazari T, Bayat R, Hamedi M. Metformin therapy in girls with polycystic ovary syndrome: a self-controlled clinical trial. Archives Iranian Med. 2007;10(2):176-81

Ashrafi M, Zafarani F, Baghestani AR. Effects of metformin on ovulation and pregnancy rate in women with clomiphene resistant polycystic ovary syndrome. Int J Fertil Steril. 2007;1(1):39

Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010;26(4):275-80.

Le Donne M, Alibrandi A, Giarrusso R, Lo MI, Muraca U. Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition. Minerva Ginecol. 2012;64(1):23-9.

Angik R, Jajoo SS, Hariharan C, Chimote A. A comparative study of metabolic and hormonal effects of myoinositol vs. metformin in women with polycystic ovary syndrome: A randomised controlled trial. Int J Reprod Contracept Obstet Gynecol. 2017;4(1):189-4.

Awalekar J, Awalekar C, Jadhav M, Chivate CG, Patwardhan MH. Effect of metformin and myoinositol and lifestyle modification in patients of PCOD. Int J Biomed Res 2015;6(09);698-704

Chirania K, Misra S, Behera S. A randomised clinical trial comparing myoinositol and metformin in PCOS. Int J Reprod Contracept Obstet Gynecol. 2017;6(5):1814-20.

Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, Apridonidze T, Iuorno MJ, Nestler JE. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabet Care. 2006;29(2):300-5.

Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. European Review Medical Pharmacol Sci. 2003 Nov;7:151-60.

Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007;23(12):700-3.

Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24:139-44.

Zacchè MM, Caputo L, Filippis S, Zacchè G, Dindelli M, Ferrari A .Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol. 2009;25(8):508-13.

Venturella R. Assessment of the modification of the clinical, endocrinal and metabolical profile of patients with PCOS syndrome treated with myo-inositol]. Minerva Gynecol, 2010; 64:239-43

Genazzani AD, Despini G, Santagni S, Prati A, Rattighieri E, Chierchia E, et al. Effects of a combination of alpha lipoic acid and myo-inositol on insulin dynamics in overweight/obese patients with PCOS. Endocrinol Metab Synd. 2014;3(140):2161-017.

Ranwa M, Nagaria T, Jaiswal J, Arya A. Study of effect of myoinositol on menstrual irregularities and skin problems in polycystic ovarian syndrome cases. Int J Reprod Contracept Obstet Gynecol. 2017;6(6):2310-7.

Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. JAPI. 2009;57(2):163-70.

Moini A, Eslami B. Familial associations between polycystic ovarian syndrome and common diseases. J Assisted Reprod Genet. 2009;26(2-3):123-7.

Saxena P, Prakash A, Nigam A, Mishra A. Polycystic ovary syndrome: Is obesity a sine qua non? A clinical, hormonal, and metabolic assessment in relation to body mass index. Indian J Endocrinol Metabol. 2012;16(6):996.